Stocks firm on Europe's last full trading day of 2021



(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window)

* France's CAC 40 outshines European benchmark YTD

* CAC 40 on track for best year since 1999

* Tech, healthcare stocks lead gains

* Credit Suisse finds second breach of COVID-19 rules by chairman (New throughout, updates prices, market activity and comments to close)

By Anisha Sircar and Shashank Nayar

Dec 30 (Reuters) - European shares ended higher on Thursday on hopes fresh curbs and restrictions may not be needed to fight the pandemic going into the new year, but a surge in COVID-19 cases due to the Omicron variant kept a lid on gains.

The pan-European STOXX 600 .STOXX rose 0.3%, up for the second straight week with the tech .SX8P sector, healthcare .SXDP and travel stocks .SXTP , in the lead.

Most European bourses including Germany's DAX .GDAXI , France's CAC40 .FCHI , Spain's IBEX .IBEX and London's FTSE 100 .FTSE were on-track to record gains for the second consecutive week.

However, risks of hawkish central banks decisions on rising inflation pressures and lingering concerns of recent jump in global Omicron cases have limited gains so far.

The European Central Bank is close to meeting its 2% medium-term inflation target and can unwind stimulus quicker than planned if price growth continues to surprise on the upside, Dutch central bank chief Klaas Knot told a German newspaper.

"Traders continue to shake off the headlines about the rising number of patients with the omicron variant ... It is worrying that case numbers are high, but the low hospitalisation rates are determining the mood in the markets," said David Madden, an analyst at Equiti Capital.

Spain's IBEX .IBEX rose 0.5% even as flash data showed consumer prices in December rose 6.7% across the country from the same month last year, the fastest annual pace of inflation since 1989.

The index has underperformed its regional peers in 2021, gaining a near 8%, compared with the STOXX 600's 22% rise.

France's CAC 40 has jumped 29.2% year-to-date, eclipsing the STOXX 600's gains, as hopes of an economic recovery boosted luxury stocks, even though the outlook for demand from Asia remains bleak into the new year.

Global COVID-19 infections hit a record high over the past seven-day period, Reuters data showed on Wednesday, as countries try to fight the pandemic while keeping economies open.

British Prime Minister Boris Johnson said this week he would not bring in new pandemic-related restrictions this year, while a curfew has been ruled out in mainland France.

Researchers said on Thursday a booster dose of Johnson & Johnson's JNJ.N COVID-19 vaccine was 84% effective at preventing hospitalisation in South African healthcare workers who became infected as Omicron spread.

Several European markets including Italy, Germany and Spain will be closed on Friday, while Paris and London will trade for half a session, ahead of the New Year.



STOXX 600 CAC 40 Link



Reporting by Anisha Sircar and Shashank Nayar in Bengaluru;
Editing by Subhranshu Sahu, Shounak Dasgupta and David Gregorio

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.